Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time...
Transcript of Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time...
![Page 1: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/1.jpg)
Pygo2 as a novel biomarker in gastric cancer for monitoring
drug resistance by upregulating MDR1
Dongdong Zhang1, Yu Liu2, Qiuwan Wu2, Yahong Zheng3, Natasha
Kaweme4, Zhiming Zhang2, Mingquan Cai2*, Youhong Dong1*
1Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei
University of Medicine, Xiangyang, Hubei 441000, China
2Department of Medical Oncology, The First Affiliated Hospital of
Xiamen University, Xiamen 361003, Fujian, China
3Xiamen Huli District Maternal and Child Health Hospital, 361005
Xiamen, Fujian, China
4Department of Hematology, Zhongnan Hospital, Wuhan University,
Wuhan, P.R. China
Correspondence
*Mingquan Cai, Department of Medical Oncology, The First
Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian,
China. Email: [email protected]
*Youhong Dong, Department of Oncology, Xiangyang No. 1
People's Hospital, Hubei University of Medicine, Xiangyang, Hubei
441000, China. Email: [email protected]
![Page 2: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/2.jpg)
Abstract: Chemotherapy is the main therapy for gastric cancer (GC) both
before and after surgery, but the emergence of multidrug resistance (MDR)
often leads to disease progression and recurrence. P-glycoprotein, encoded
by MDR1, is a well-known multidrug efflux transporter involved in drug
resistance development. Pygo2 overexpression has been identified in
several cancers. Previous studies have shown that abnormal expression of
Pygo2 is related to tumorigenesis, chemoresistance, and tumor progression.
In this study, to evaluate the underlying relationship between Pygo2 and
MDR1 in GC, we constructed GC drug-resistant cell lines, SGC7901/cis-
platinum (DDP), and collected tissue from GC patients pre-and post-
chemotherapy. We found that Pygo2 was overexpressed in GC, especially
in GC drug-resistant cell lines and GC patients who underwent neoadjuvant
DDP-based chemotherapy. Pygo2 overexpression may precede MDR1 and
correlates with MDR1 in GC patients. Furthermore, knock-down of Pygo2
induced downregulation of MDR1 and restored SGC7901/DDP’s
sensitivity to DDP. Further mechanistic analysis demonstrated that Pygo2
could modulate MDR1 transcription by binding to the MDR1 promoter
region and promoting MDR1 activation. The overall findings reveal that
Pygo2 may be a promising biomarker for monitoring drug resistance in GC
by regulating MDR1.
Keywords: Pygo2, gastric cancer, biomarker, drug resistance, MDR1
![Page 3: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/3.jpg)
1. Introduction
Gastric cancer (GC) has relatively high morbidity and mortality rate
around the world. Although surgery is the first choice of treatment,
chemotherapy also plays an important role in treating GC as GC has a low
incidence of early diagnosis. Neoadjuvant chemotherapy can diminish
tumor volume, degrade tumor stage, and increase the resection rate.
Postoperative chemotherapy can prevent tumor recurrence and metastasis,
thus prolonging the overall survival. Palliative chemotherapy can alleviate
clinical symptoms and improve the quality of life of patients. However,
multidrug resistance (MDR) can eventually result in chemotherapy failure.
Therefore, early detection of MDR in GC patient is essential.
Cancer cells can pump various chemotherapeutic drugs out of the cell
by drug efflux transporters [1]. The occurrence of MDR is accompanied by
the overexpression of multidrug efflux transporters, with the most
extensively studied being multidrug resistance protein 1 (MDR1) [2]. P-
glycoprotein, encoded by ATP-binding cassette subfamily B member 1
(ABCB1) or MDR1, can induce multidrug resistance by increasing drug
efflux and decreasing intracellular drug concentration [3]. The
overexpression of MDR1 was identified in some intrinsically drug-
resistant digestive system tumors such as colorectal carcinoma,
hepatocellular carcinoma, pancreatic cancer [4, 5], and other tumors [2].
Furthermore, MDR1 overexpression in breast cancer often indicated a
![Page 4: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/4.jpg)
more malignant phenotype [6] and a higher recurrence rate [7]. To date, the
molecular modulation mechanism of MDR1 in gastric cancer is still
unclear.
Pygopus2 (Pygo2) was initially identified as a novel functional protein
of the Wingless pathway downstream in Drosophila [8]. Further studies
showed Pygo2 could regulate the Wnt/β-catenin pathway via linking
Pygo2 PHD domain to β-catenin [9] and activating T-cell factor
(TCF)/lymphoid-enhancing factor 1 (LEF) transcription [10]. Pygo2
played an important role in transcription regulation, tissue differentiation
and embryonic development [11, 12]. Pygo2 is usually maintained at a low
level in normal cells but has shown an abnormally high expression level in
some cancers. Overexpression of Pygo2 acted as a driver for metastatic
prostate cancer and esophageal squamous cell carcinoma by enhancing
tumor growth and invasion [13, 14]. Abnormal expression of Pygo2 also
suggested a malignant phenotype in advanced lung cancer [15]. Moreover,
Pygo2 overexpression was associated with chemoresistance and poor
prognosis in breast cancer and hepatocellular carcinoma [7, 16]. Inhibition
of Pygo2 expression increased the sensitivity of breast cancer cells to
chemotherapeutic drugs and suppressed tumor growth [17]. However, the
expression level of Pygo2 in GC and the relationship between Pygo2 and
MDR1 was undefined. In the present study, we detected the expression
level of MDR1 and Pygo2 in GC and explored the functional relationship
![Page 5: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/5.jpg)
between them.
2. Materials and methods
2.1 Materials
Cis-platinum (DDP) was obtained from the first affiliated hospital of
Xiamen University. MDR1 (ABCB1, Cat# sc-55510) and β-actin (Cat# sc-
47778) antibodies were purchased from Santa Cruz Biotechnology. Pygo2
(Cat# 11555-1-AP) antibody was obtained from Proteintech and TIAN
pure Midi Plasmid Kit (Cat# DP107) from TIANGEN. TurboFect
Transfection Reagent (Cat# R0531) was from Thermo Scientific. E.coli
pLL3.7-hPygo2-KD (knock-down) and pGL3.3-control were a gift from
Xiamen University School of Life Sciences.
2.2 Cell culture and specimen collection
The GC cell lines, SGC7901 and SGC7901/DDP were cultured in
DMEM medium with 10% fetal bovine serum and 1%
penicillin/streptomycin. The GC tissues were collected from 40 GC
patients using gastroscopy and surgery. All the GC patients were treated
with platinum-based neoadjuvant chemotherapy, including combined with
capecitabine, tegafur gimeracil oteracil potassium capsule (S-1),
doxorubicin (ADM) and 5-fluorouracil (5-Fu). Importantly, all subjects
were given written informed consent in accordance with the
![Page 6: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/6.jpg)
recommendations of Ethics and Scientific Committee of The First
Affiliated Hospital of Xiamen University and the Declaration of Helsinki,
the approved number from the Ethics committee of Xiamen University is
2019118.
2.3 MTT assay
Cell viability was measured by using the MTT method. Briefly,
SGC7901 and SGC7901/DDP cells (5×105/well) were seeded in 96-well
plates for 24 h, then treated with different concentrations of DDP for 24 h.
Thereafter, cells were labeled with 20 μL MTT labeling reagent, and
absorbance at 570 nm was determined with a microplate reader.
2.4 The construction of drug resistance SGC7901/DDP
The SGC7901/DDP cell was constructed by treatment with increasing
DDP concentration repeatedly and gradually. Firstly, SGC7901 cells were
seeded at plates and treated with initial DDP concentration at 0.1 μg/mL
for 24h, then the medium was removed, and the cells were transferred to
fresh medium. The above procedures were repeated, and DDP
concentration was increased gradually until the cell apoptosis rate was
above 90%. Cell morphology was observed by microscopy.
2.5 Cell apoptosis assay
Cell apoptosis rate was determined by flow cytometry analysis using
Annexin V-FITC Apoptosis Detection Kit (KEYGEN Biotech, Cat#
KGA105-KGA108). 5×105 cells were seeded in 6-well plates and treated
![Page 7: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/7.jpg)
with 0.4 μg/mL DDP for 24 h. The collected cells were washed by PBS
twice and then labeled with 5 μL Annexin V-FITC and 5 μL Propidium
iodide for 5 minutes at 25 ℃. The stained cells were analyzed by flow
cytometry using CytExpert2.0 software.
2.6 Western blot assay (WB)
Total protein extracts were prepared, and the protein concentration was
measured as described previously [18]. Generally, 15 μg protein was
separated by 10% SDS-PAGE and transferred onto PVDF membrane, then
blocked with 5% fat-free milk and incubated with primary antibodies and
HRP- conjugated secondary antibodies. The protein levels were detected
by using the Enhanced Chemiluminescent (ECL) Detection Kit (Boster,
Cat# EK1001).
2.7 Real-time quantitative PCR
Total RNAs were homogenized in Trizol and isolated, as described in
our previous study [19]. Then cDNAs were reversely transcribed by using
PrimeScriptTM RT reagent kit with gDNA Eraser (Takara, Cat# RR047A).
The expression levels of MDR1 and Pygo2 were detected using SYBR
GREEN MIXTURE kit (Bio-Rad, Cat# 10000076382) and analyzed by
comparing to β-actin. The primers are listed below: Pygo2, Forward Primer:
5’-GTTTGGGCTGTCCTGAAAGTCTG-3’, Reserve Primer: 5’-
ATAAGGGCGCCGAAAGTTGA-3’; MDR1, Forward Primer: 5’-
AGCTCGTGCCCTTGTTAGACA-3’, Reserve Primer: 5’-
![Page 8: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/8.jpg)
GTCCAGGGCTTCTTGGACAA-3’; β-actin, Forward Primer: 5’-
CGAGCGGGAAATCGTGCGTGACATTAAGGAGA-3’, Reserve
Primer: 5’-CGTCATACTCCTGCTTGATCCACATCTGC-3’.
2.8 Immunohistochemistry (IHC)
GC tissues were fixed and cut into slices, then processed and incubated
with primary antibodies and probed with secondary antibody. The detailed
protocol could refer to our previous work [19]. Images were captured by
using a Nikon microscope.
2.9 pLL3.7- hPygo2-knock-down (KD) transfection
SGC7901/DDP cells were transfected with pGL3.3-Control and
pLL3.7-hPygo2-KD plasmid using TurboFect Transfection Reagent
following the manufacturer’s instructions. Briefly, short hairpin targeted
Pygo2 (Pygo2 shRNA) and the scramble control sequences (SCR shRNA)
were designed based on hPygo2 sequences and further synthesized for the
construction of plasmids [20]. The detailed hPygo2 sequences could be
referred to GenBank with accession number NW_925683. The primers
were listed as follow: SCR shRNA, Forward Primer: 5’-
GATCCCCGTGGTTTCATCGCATCTGCTTCAAGAGAGCAGATGCG
ATGAAACCACTTTTTA-3’, Reserve Primer: 5’-
AGCTTAAAAAGTGGTTTCATCGCATCTGCTCTCTTGAAGCAGAT
GCGATGAAACCACGGG-3’; Pygo2 shRNA, Forward Primer: 5’-
GATCCCCTGTGAGGCCTCTTGTCAGAAATTCAAGAGATTTCTGA
![Page 9: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/9.jpg)
CAAGAGGCCTCACATTTTTA-3’, Reserve Primer: 5’-
GGGACACTCCGGAGAACAGTCTTAAGTTCTCTAAAGACTGTTC
TCCGGAGTGTAAAAATTCGA-3’. The lentiviral pLL3.7 vector (X-Y
Biotechnology, Cat# XY2204) was used to express Pygo2 shRNA and
pGL3.3 vector (Promega, Cat# E1741) served as a control, the plasmids
were obtained by using TIAN pure Midi Plasmid Kit and the detailed
procedures were described previously [21]. The transient transfection was
observed under a fluorescence microscope and verified by WB.
2.10 Luciferase reporter analysis
The pGL6-MDR1 reporter plasmid, which contained the MDR1
promoter region was constructed in our lab and described in our previous
study [22]. The pGL6 reporter plasmid (318 bp) was designed as below:
forward primer: 5′-CAGGGTACCAGTTGAAATGTCCCCAATGAT-3′,
reverse primer: 5′-CCTAGATCTGGAAAGACCTAAAGGAAACGAAC-
3′. Briefly, SGC7901/DDP cells were transfected with the pGL6-MDR1
reporter plasmid, and cell homogenate was lysed and collected for
luciferase reporter analysis.
2.11 Chromatin immunoprecipitation (ChIP) assay
The primers for ChIP on MDR1 were designed as described previously
[22]. MDR1 primers were listed as below: forward primer: 5′-
GCGTTTCTCTACTTGCCCTTTC-3′, reverse primer: 5′-
AGCCAATCAGCCTCACCACAG-3′. ChIP assay was performed by
![Page 10: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/10.jpg)
using a ChIP assay kit (Merck-Millipore, Cat# 17–371) per to the
manufacturer’s recommendations.
2.11 Statistical analysis
The experiments such as MTT assay, WB and RT-PCR were performed
in triplicate and data was expressed as the mean ± SD. Collective data was
then analyzed using student’s t-test and chi-square test. Correlation
analysis was processed by using GraphPad Prism 7.0. P<0.05 was defined
as the statistical significance and represented with *. *P<0.05, **P<
0.01,***P<0.001, ****P<0.0001.
3. Results
3.1 SGC7901/DDP was insensitive to chemotherapeutic drugs
We successfully constructed GC drug resistance cell SGC7901/DDP
after six months utilizing the method described above. Comparing to
SGC7901, SGC7901/DDP had a smaller cell volume, and its cell shape had
changed from long spindle to short polygon. Furthermore, SGC7901/DDP
had a slower breeding rate and showed monoclonal colony growth (Fig.
1A). SGC7901/DDP was insensitive to a low concentration of DDP when
cells were exposed to different concentrations of DDP (Fig. 1B). The
median IC50 value of SGC7901/DDP in 24 h was 0.89 μg/mL, which was
significantly higher than SGC7901 with a median IC50 value in 24 h was
0.35 μg/mL (Fig. 1C). ADM and 5-Fu were also commonly prescribed to
![Page 11: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/11.jpg)
treat GC, we found that SGC7901/DDP was also insensitive to 5-Fu and
ADM compared to SGC7901. The median IC50 values of 5-Fu and ADM
in SGC7901/DDP for 24 h were 109.1 μg/mL and 1.3 μg/mL, which were
higher than 20.5 μg/mL and 0.5 μg/mL in SGC7901 (Fig. 1C).
3.2 High expression of Pygo2 and MDR1 in SGC7901/DDP and GC
patients after chemotherapy
Firstly, we detected the protein and mRNA expression levels of Pygo2
and MDR1 in SGC7901/DDP by WB and RT-PCR. Our results showed
that SGC7901/DDP had higher expression levels of Pygo2 and MDR1
compared with SGC7901 (Fig 2A and 3A). Next, we analyzed Pygo2 and
MDR1 expression levels in normal-appearing tissue adjacent to GC (NaT),
GC tissue (GcT) and GC tissue after neoadjuvant chemotherapy (NeC).
Our data revealed that MDR1 and Pygo2 was low or rarely expressed in
NaT but were highly expressed in GcT and with highest expression levels
in NeC (Fig 2A, Fig 2B and 3B).
3.3 Pygo2 overexpression preceded MDR1 and Pygo2 correlated with
MDR1
We analyzed 40 GC patients in the first affiliated hospital of Xiamen
University who had undergone neoadjuvant DDP-based chemotherapy.
Our results showed that 15% (6/40) of GC patients were Pygo2
overexpression positive, and 5% (2/40) were MDR1 overexpression
positive pre-chemotherapy. While amongst the group, 62.5% (25/40) of
![Page 12: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/12.jpg)
GC patients were Pygo2 overexpression positive, and 45% (18/40) were
MDR1 overexpression positive post-chemotherapy. The results indicated
that Pygo2 overexpression might precede MDR1 (Table 1). Furthermore,
analyzing the two genes across online data sets showed that a strong
correlation between Pygo2 and MDR1 expression levels after
chemotherapy in GC tissue (Fig 3C).
3.4 The knock-down of Pygo2 induced MDR1 downregulation and
rendered GC cell sensitive to chemotherapeutic drugs
To clarify the relationship between Pygo2 and MDR1 in GC, we
suppressed Pygo2 expression in SGC7901/DDP by transfecting pLL3.7-
hPygo2-KD plasmid. We proceeded to perform WB to determine whether
Pygo2 was successfully suppressed (Fig 4A). The results suggested that
when Pygo2 was inhibited, MDR1 expression was also downregulated (Fig
4B). In addition, GC drug resistance cell SGC7901/DDP became sensitive
to chemotherapeutic drugs when Pygo2 was knocked down (Fig 4C).
3.5 Pygo2 promoted MDR1 activation by interacting with MDR1
To illuminate the role of Pygo2 in the activation of MDR1, we
performed luciferase reporter analysis. We found that Pygo2 could promote
the activation of MDR1 promoter (Fig 4D). Further mechanism analysis
by ChIP assay verified the association of Pygo2 with the MDR1 promoter
region (Fig 4E). One other point worth emphasizing is our previous study
also demonstrated Pygo2 could modulate MDR1 activation in breast
![Page 13: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/13.jpg)
cancer by directly binding to β-catenin, thus regulating the Wnt/β-catenin
signaling pathway [7].
Taking into consideration the obtained results; we can conclude that
the overexpression of Pygo2 promotes MDR1 activation and is involved in
DDP drug resistance in GC.
4. Discussion
Majority of GC patients are diagnosed at advanced stage disease as GC
has a relatively low early detection and diagnosis rate. Chemotherapy is an
important alternative therapeutic method for these patients. However, the
development of MDR not only causes failure of the first-line treatment
recommended by National Comprehensive Cancer Network (NCCN), but
also results in the ineffectiveness of the second-and third-line solutions
[23]. Therefore, it is important to elucidate the mechanism of
chemoresistance.
Studies exploring the mechanism of drug resistance are mainly divided
into the following categories: alterations in drug efflux [24], dysfunction
of DNA damage repair [25], disruption of apoptosis balance such as
overexpression of anti-apoptosis proteins [26] and mutation of drug targets
[27]. One of the most studied mechanism is overexpression of MDR1 and
multi-drug resistant associate protein (MRP), which serve as drug efflux
transporters leading to a decrease in intracellular drug concentration [28].
![Page 14: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/14.jpg)
MDR1 overexpression was identified in GC cell lines and primary GC
tissue in previous studies [29]. Additionally, MDR1 overexpression was
negatively associated with chemosensitivity [30]. Studies on MDR
transporter inhibitors have been flourishing, but with little success [31].
Hence, it was essential to identify novel MDR biomarkers and drug targets.
Pygo2 is a novel effector protein, downstream of the Wnt/β-catenin
signaling pathway, that acts as a co-activator with β-catenin to promote β-
catenin/LEF/TCF activation [32]. Abnormal expression of Pygo2 has been
reported in several cancers such as breast cancer, glioma, esophageal
squamous cell carcinoma, hepatocellular carcinoma and prostate cancer [7,
13, 14, 16, 33-35]. Furthermore, Pygo2 overexpression was associated with
tumor initiation and progression, malignant phenotype, and poor prognosis
[13, 15, 16, 34]. Inhibition of Pygo2 suppressed tumor growth, invasion,
and epithelial-mesenchymal transition (EMT) [17]. Our previous study
showed that Pygo2 was associated with chemoresistance in breast cancer
by activating MDR1 [7]. MDR1 was the downstream target of the Wnt/β-
catenin signaling pathway, and it was upregulated when the Wnt/β-catenin
was activated [36]. Pygo2 not only promoted Wnt/β-catenin activation but
also modulated Wnt/β-catenin activity in tissue-and gene-dependent
manner [11, 37, 38]. Thus, whether Pygo2 regulates MDR1 in GC or not
still needs further study.
These recent findings verified that Pygo2 and MDR1 were
![Page 15: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/15.jpg)
overexpressed in GC, especially in GC patients after chemotherapy. Pygo2
overexpression precedes MDR1 and Pygo2 strongly correlated with MDR1
in GC patients who underwent neoadjuvant chemotherapy. The Knock-
down of Pygo2 could restore the drug-resistant cell SGC/7901 sensitivity
to chemotherapeutic drugs. Further mechanism analysis indicated that
Pygo2 could promote MDR1 activation by binding to the MDR1 promoter
region. These results demonstrated that Pygo2 might be a novel biomarker
for monitoring drug resistance by upregulating MDR1. This study also
provided a potential therapeutic target in the treatment of cancers where
Pygo2 is overexpressed.
In conclusion, Pygo2 and MDR1 were overexpressed in GC patients
after chemotherapy. Pygo2 played a pivotal role in drug resistance in GC
by promoting MDR1 activation. Pygo2 may be a novel biomarker for
monitoring drug resistance and a potential therapeutic target for cancer
treatment in the future.
Acknowledgements
We appreciate the support from Professor Bo-an Li for designing the
pLL3.7-hPygo2-KD and pGL3.3-control at the Department of Biomedical
Sciences, Xiamen University School of Life Sciences, Xiang’an Campus
of Xiamen University.
![Page 16: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/16.jpg)
Funding
This work was supported by the Natural Science Foundation of Fujian
program (grant number 2019J01575) and the Hubei Education Program
(grant number JX5B78).
Authors’ contributions
MQC and YHD provided the direction of study. DDZ performed the
major experiments, analyzed the data and wrote the manuscript, QWW
guided the experiments. YHZ contributed to the specimen collection and
contributed to the cell experiments. YL helped analyzing the ICH. NK and
ZMZ helped revise the manuscript. All authors read and approved the final
manuscript.
Conflict of interests
The authors declare that they have no competing interests
Data availability statement
![Page 17: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/17.jpg)
The raw data supporting the conclusions of this manuscript will be
made available by the authors.
![Page 18: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/18.jpg)
References
1. Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and
strategies for drug development. Current pharmaceutical design. 2014; 20: 793-807.
2. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of
ABC transporters in multidrug-resistant cancer. Nature reviews Cancer. 2018; 18: 452-64.
3. Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of Genetic Polymorphisms of
ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of
the Literature. Clinical pharmacokinetics. 2015; 54: 709-35.
4. Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC Transporters:
Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal
Carcinoma. Current medicinal chemistry. 2019; 26: 1224-50.
5. Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome
of pancreatic cancer: What is the way forward? World journal of gastroenterology. 2018; 24: 3222-
38.
6. Levi M, Brunetti B, Sarli G, Benazzi C. Immunohistochemical Expression of P-glycoprotein and
Breast Cancer Resistance Protein in Canine Mammary Hyperplasia, Neoplasia and Supporting
Stroma. Journal of comparative pathology. 2016; 155: 277-85.
7. Zhang ZM, Wu JF, Luo QC, Liu QF, Wu QW, Ye GD, et al. Pygo2 activates MDR1 expression
and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway. Oncogene. 2016;
35: 4787-97.
8. Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M. A new nuclear component
of the Wnt signalling pathway. Nature cell biology. 2002; 4: 367-73.
9. Kessler R, Hausmann G, Basler K. The PHD domain is required to link Drosophila Pygopus to
Legless/beta-catenin and not to histone H3. Mechanisms of development. 2009; 126: 752-9.
10. Chen J, Luo Q, Yuan Y, Huang X, Cai W, Li C, et al. Pygo2 associates with MLL2 histone
methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene
expression and breast cancer stem-like cell expansion. Molecular and cellular biology. 2010; 30:
5621-35.
11. Gu B, Sun P, Yuan Y, Moraes RC, Li A, Teng A, et al. Pygo2 expands mammary progenitor
cells by facilitating histone H3 K4 methylation. The Journal of cell biology. 2009; 185: 811-26.
12. Schwab KR, Patterson LT, Hartman HA, Song N, Lang RA, Lin X, et al. Pygo1 and Pygo2 roles
in Wnt signaling in mammalian kidney development. BMC biology. 2007; 5: 15.
13. Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, et al. An In Vivo Screen Identifies PYGO2 as a
Driver for Metastatic Prostate Cancer. Cancer research. 2018; 78: 3823-33.
14. Moghbeli M, Sadrizadeh A, Forghanifard MM, Mozaffari HM, Golmakani E, Abbaszadegan
MR. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. Journal
of cell communication and signaling. 2016; 10: 49-53.
15. Liu Y, Dong QZ, Wang S, Fang CQ, Miao Y, Wang L, et al. Abnormal expression of Pygopus 2
correlates with a malignant phenotype in human lung cancer. BMC cancer. 2013; 13: 346.
16. Zhang S, Li J, He F, Wang XM. Abnormal nuclear expression of Pygopus-2 in human primary
hepatocellular carcinoma correlates with a poor prognosis. Histopathology. 2015; 67: 176-84.
![Page 19: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/19.jpg)
17. Chi Y, Wang F, Zhang T, Xu H, Zhang Y, Shan Z, et al. miR-516a-3p inhibits breast cancer cell
growth and EMT by blocking the Pygo2/Wnt signalling pathway. Journal of cellular and molecular
medicine. 2019; 23: 6295-307.
18. Zhang D, Liu Y, Luo Z, Chen Y, Xu A, Liang Y, et al. The novel thioredoxin reductase inhibitor
A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia.
Free radical biology & medicine. 2020; 146: 275-86.
19. Dongdong Z, Jin Y, Yang T, Yang Q, Wu B, Chen Y, et al. Antiproliferative and
Immunoregulatory Effects of Azelaic Acid Against Acute Myeloid Leukemia via the Activation of
Notch Signaling Pathway. Frontiers in pharmacology. 2019; 10: 1396.
20. Wang ZX, Chen YY, Li BA, Tan GW, Liu XY, Shen SH, et al. Decreased pygopus 2 expression
suppresses glioblastoma U251 cell growth. Journal of neuro-oncology. 2010; 100: 31-41.
21. Xie YY, Mo CL, Cai YH, Wang WJ, Hong XX, Zhang KK, et al. Pygo2 Regulates Adiposity and
Glucose Homeostasis via β-Catenin-Axin2-GSK3β Signaling Pathway. Diabetes. 2018; 67: 2569-
84.
22. Chen S, Wang H, Li Z, You J, Wu QW, Zhao C, et al. Interaction of WBP2 with ERα increases
doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. British journal of
cancer. 2018; 119: 182-92.
23. Thiels CA, Hanson KT, Habermann EB, Boughey JC, Grotz TE. Integrated cancer networks
improve compliance with national guidelines and outcomes for resectable gastric cancer. Cancer.
2020; 126: 1283-94.
24. Cui H, Zhang AJ, Chen M, Liu JJ. ABC Transporter Inhibitors in Reversing Multidrug Resistance
to Chemotherapy. Current drug targets. 2015; 16: 1356-71.
25. Özeş AR, Miller DF, Özeş ON, Fang F, Liu Y, Matei D, et al. NF-κB-HOTAIR axis links DNA
damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. 2016;
35: 5350-61.
26. Xia H, Hui KM. Mechanism of cancer drug resistance and the involvement of noncoding RNAs.
Current medicinal chemistry. 2014; 21: 3029-41.
27. Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current Challenges
in Cancer Treatment. Clinical therapeutics. 2016; 38: 1551-66.
28. Cole SP. Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette
(ABC) transporter. The Journal of biological chemistry. 2014; 289: 30880-8.
29. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer. 1993;
71: 667-71.
30. Li Y, Tan BB, Zhao Q, Fan LQ, Liu Y, Wang D. Regulatory mechanism of ZNF139 in multi-drug
resistance of gastric cancer cells. Molecular biology reports. 2014; 41: 3603-10.
31. Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC transporter-mediated
multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug
resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
2016; 27: 14-29.
32. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the
nucleus to enable its transcriptional co-activator function. Nature cell biology. 2004; 6: 626-33.
33. Moghbeli M, Abbaszadegan MR, Farshchian M, Montazer M, Raeisossadati R, Abdollahi A, et
al. Association of PYGO2 and EGFR in esophageal squamous cell carcinoma. Medical oncology
(Northwood, London, England). 2013; 30: 516.
![Page 20: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/20.jpg)
34. Watanabe K, Fallahi M, Dai X. Chromatin effector Pygo2 regulates mammary tumor initiation
and heterogeneity in MMTV-Wnt1 mice. Oncogene. 2014; 33: 632-42.
35. Li M, Chao L, Wu J, Xu H, Shen S, Chen S, et al. Pygo2 siRNA Inhibit the Growth and Increase
Apoptosis of U251 Cell by Suppressing Histone H3K4 Trimethylation. Journal of molecular
neuroscience : MN. 2015; 56: 949-55.
36. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, et al. The Wnt receptor FZD1
mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Oncogene. 2009; 28: 2245-56.
37. Sun P, Watanabe K, Fallahi M, Lee B, Afetian ME, Rheaume C, et al. Pygo2 regulates β-
catenin-induced activation of hair follicle stem/progenitor cells and skin hyperplasia. Proceedings
of the National Academy of Sciences of the United States of America. 2014; 111: 10215-20.
38. Gu B, Watanabe K, Sun P, Fallahi M, Dai X. Chromatin effector Pygo2 mediates Wnt-notch
crosstalk to suppress luminal/alveolar potential of mammary stem and basal cells. Cell stem cell.
2013; 13: 48-61.
![Page 21: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/21.jpg)
Table1. The expression status of Pygo2 and MDR1 in GC patient pre-and post-
operation.
Group
Pre chemotherapy
(Gastroscopy)
Post chemotherapy
(Postoperative biopsy)
χ2-test
P value
Pygo2 Overexpression 6(15%) 25(62.5%)
<0.0001 None overexpression 34 (85%) 15(37.5%)
MDR1 Overexpression 2(5%) 18(45%)
<0.0001 None overexpression 38(95%) 22(55%)
![Page 22: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/22.jpg)
Figure 1. The construction of GC drug resistance cell SGC7901/DDP. (A):
SGC7901 and SGC7901/DDP was observed by using a microscopy and the images
were captured, magnification: ×40. (B): SGC7901 and SGC7901/DDP cells were
treated with different concentrations of DDP, 5-Fu and ADM for 24 h and the cell
viability was measured by MTT assay. (C): IC50 of DDP, 5-Fu and ADM in SGC7901
and SGC7901/DDP. Each experiment was repeated three times, **P<0.01. ***P<
0.001. DDP: cis-platinum; ADM :Adriamycin; 5-Fu:5-fluorouracil.
![Page 23: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/23.jpg)
Figure 2. Pygo2 and MDR1 were overexpression in GC cell lines and GC patients
after chemotherapy. (A): The Pygo2 and MDR1 protein expression levels were detected
by WB. (B): The expression levels of Pygo2 and MDR1 in GC tissue measured by IHC,
magnification: ×40. IHC: immunohistochemistry; NaT: normal-appearing tissue
adjacent to GC, GcT: GC tissue; NeC: GC tissue after neoadjuvant chemotherapy.
![Page 24: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/24.jpg)
Figure 3. Pygo2 overexpression was strong corelated with MDR1. The Pygo2 and
MDR1 RNA expression levels were detected by RT-PCR in GC cell lines (A) and GC
tissues (B). (C): The Pearson’s R correlation was analyzed between Pygo2 and MDR1
expression levels in GC patients after chemotherapy. NaT: normal-appearing tissue
adjacent to GC, GcT: GC tissue; NeC: GC tissue after neoadjuvant chemotherapy.
![Page 25: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/25.jpg)
Figure 4. Pygo2 modulated MDR1 expression in GC. (A): The knock-down of
Pygo2 down was identified by WB after transfection. (B): The expression levels of
Pygo2 and MDR1 in SGC7901/DDP-pLL3.3-Pygo2-KD and SGC7901/DDP-pGL3.3.
(C): SGC7901/DDP-pLL3.3-Pygo2-KD and SGC7901/DDP-pGL3.3 were treated with
0.4 μg/mL DDP for 24 h, the apoptosis rate was analyzed by flow cytometry. (D):
SGC7901/DDP cells were transfected with the indicated plasmids and MDR1-reporter
gene luciferase activity was measured. (E):The interaction between Pygo2 and MDR1
promoter region using anti-Pygo2 antibody in SGC7901/DDP and GC tissue after
neoadjuvant chemotherapy (Nec) by ChIP assay. ***P<0.001.
![Page 26: Pygo2 as a novel biomarker in gastric cancer for monitoring ...Cat# EK1001). 2.7 Real-time quantitative PCR Total RNAs were homogenized in Trizol and isolated, as described in our](https://reader035.fdocuments.in/reader035/viewer/2022070214/61133bffcc9aa9115c0d2ef3/html5/thumbnails/26.jpg)